As always another professional preso.. some key takeaways I spotted..
"Competitive products with less ideal safety profiles and potentially poorer efficacy, have generated more than US $1bn per annum"
"BTX 1503 is a safe and well tolerated topical acne treatment that potentially addresses all the key causes of acne" (Loved the use of the world potentially) -
"Papulopustular rosacea is a chronic skin disease characterised by redness (inflammation) and acne like break-out
Hints everywherre.. One must ask why the rosacea now? Perhaps the 'acne like break-out' is the key takeaway? Why chase a similiar market otherwise?
Join the dots..
Phase 1B for BTX 1702 will only take 6 weeks also.. then straight on to phase 2 no doubt.
Also great to see some patent explanation.. that's the beauty of having an ex patent attorney I guess..
Not sure what else we can ask from management.
Great work.
(20min delay)